News News Daily digests from key neurology conferences, written by on-site medical journalists. Published: May 23, 2020

NfL stronger biomarker than mHTT for progression and brain atrophy in Huntington’s disease

Neurofilament light chain (NfL) is a stronger biomarker for progression and brain atrophy than mutant huntingtin (mHTT) in Huntington’s disease (HD) and could be used to inform clinical trial design, specialists have reported.